HopeStage
Back to all studies
CompletedNCT00833976

Omega-3 Fatty Acids (Lovaza) for Second Generation Antipsychotic-Associated Hypertriglyceridemia

Medication studyAges 18–75United StatesSchizophrenia
The study in practice

Understand this study

Who was this study for?

Listed age limits: 18 years to 75 years.

Listed locations
BostonSee all locations and recruitment
Study phase
Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.

Get this study by email

HopeStage may email me about this study.
Loading the security check...
Study clarity

Study information

Study start dateJuly 2009
Recruitment status
Completed
Enrollment listed in the registry
65
Sponsor
Massachusetts General Hospital
Sponsor type
Hospital / academic medical center
Study type
Drug
Intervention type
Drug
Study phase
Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
Locations
United States
Age range
From 18 Years to 75 Years
Official registry ID
NCT00833976
Official title
Show the full official title

Omega-3 Fatty Acids (Lovaza) for Second Generation Antipsychotic-Associated Hypertriglyceridemia

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

Boston

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

Who is behind this study?

The study sponsor is Massachusetts General Hospital, a hospital or academic medical center.

Did this study involve medication?

Yes. The study involved medication, including Lovaza.

Who was this study for?

Listed age limits: 18 years to 75 years.

Want to explore more studies?

Explore studies